Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it will be presenting at Wall Street Reporter's livestream conference on Wednesday July 29, 2020.
Mr. Steve Saviuk, CEO of Valeo will share an overview of the depth and diversity of Valeo's growing product portfolio, the four products scheduled for launch this summer and how these launches and the upcoming Redesca approval expected for late summer will help the Company move towards profitability.
Valeo presentation will take place at 1 pm EST on Wednesday, July 29, 2020.
Following the 20-minute presentation, Mr Saviuk will take questions from the audience.
To sign up for the event, https://www.wallstreetreporter.com/next-superstock-onlineinvestor-conference/
Recent company highlights include:
Notice of Compliance received from Health Canada authorizing the transfer of the AmetopTM commercial rights to Valeo.
The approval for its Abbreviated New Drug Application ("ANDA") received from the U.S. Food and Drug Administration ("FDA") for Ethacrynate Sodium 50 mg.
The notice of a positive recommendation received from Quebec's Institut national d'excellence en santé et en services sociaux ("INESSS") to the Health Minister for the inclusion of Onstryv® on the list of medications covered by the Régie de l'assurance maladie du Québec (RAMQ).
The acceptance for review of its New Drug Submission filed for a low molecular weight heparin biosimilar by Health Canada.